Study of a new antifungal treatment for stubborn fungal infections
Part of Infections, Lungs & breathing, Skin clinical trials.
This study tests a new antifungal treatment for people with certain fungal infections (Valley fever, blastomycosis, histoplasmosis) who have not done well on or can't take their current medicine. The goal is to find a better way to control the infection when the first treatment fails or causes problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a fungal infection such as Valley fever (coccidioidomycosis), blastomycosis, or histoplasmosis.
- You are 18 years old or older.
- You are currently taking antifungal medicine, and your doctor expects you will need it for at least 6 more months.
- Your current treatment has not worked well enough, caused bad side effects, or is not available to you.
- You are not currently in the hospital.
- The infection has not spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations and timing of antifungal medicines to treat histoplasmosis, a lung infection, in hospitalized patients. It aims to find the safest and most effective way to cure the infection.
This study tests a new antifungal medicine called olorofim, combined with standard care, for people with Valley fever that has spread beyond the lungs and hasn't improved with usual treatments. The goal is to see if it helps control the infection better than standard care alone.
This study looks at why “Valley fever” is difficult to treat or has spread beyond the lungs, and how a person’s genetics may be involved. You may be asked for blood or other samples for genetic testing and for storing samples for future research.
This trial tests a new drug called olorofim for people recently diagnosed with coccidioidomycosis (Valley fever) meningitis, a serious fungal infection of the brain lining. It aims to see if the drug is safe and effective as an early treatment.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
Hear when a new Coccidioidomycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.